Cascade CGM 15-day Performance Assessment

Inclusion Criteria: * • Signed informed consent form * Diagnosis of type 1 or type 2 (on insulin therapy) diabetes mellitus for at least 6 months * 18 years of age or older * Currently self-monitoring capillary blood glucose (on average at least three times per day or more) or on a CGM for at least three months * Willing to have blood glucose levels manipulated into high and low glucose levels during in clinic days if deemed appropriate per the protocol based on insulin use. * Willing to follow all study procedures, including attending all clinic visits during which a venous line will be inserted for blood sampling, wearing CGM sensors for entire study, performing fingertip glucose tests for self-monitoring and calibration, and keeping a diary of activities. * Be willing to wear two investigational CGM devices. Exclusion Criteria: * • Known allergy to medical grade adhesives * Magnetic Resonance Imaging (MRI) scheduled during CGM sensor wear period * Persons with type 2 diabetes using diet and exercise only for diabetes management * Used an investigational drug within 30 days prior to study entry * Hematocrit \< 32% (obtained during screening) * Inadequate veins (in the opinion of the investigator) or known contraindication to placement of a dedicated peripheral line for venous blood withdrawal * Symptomatic coronary artery disease with a history of angina, or history of a myocardial infarction or coronary intervention (e.g., percutaneous transluminal coronary angioplasty \[PTCA\], stent placement), or coronary artery bypass graft (CABG) within the past six months * Diagnosis of the following diabetic autonomic neuropathies: orthostatic hypotension, heart rate anomalies, gastroparesis * Cerebrovascular incident within the past six month * History or presence of eczema, psoriasis, atopic or contact dermatitis * Subject is pregnant at the start of the study. * Current use or within one-week exposure to topical medications at the proposed insertion sites * Seizure disorder (epilepsy) * Malignancy within the past five years, except basal cell or squamous cell skin cancers * Major surgical operation within 30 days prior to screening * Other medical conditions that would pose safety concerns, interfere with study conduct or seriously compromise study integrity (reason for exclusion will be clearly documented by investigator or designee)